A detailed history of Jane Street Group, LLC transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 45,159 shares of FULC stock, worth $152,185. This represents 0.0% of its overall portfolio holdings.

Number of Shares
45,159
Previous 119,893 62.33%
Holding current value
$152,185
Previous $428,000 50.47%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

SELL
$2.97 - $4.84 $221,959 - $361,712
-74,734 Reduced 62.33%
45,159 $212,000
Q3 2024

Nov 14, 2024

SELL
$3.18 - $9.74 $153,756 - $470,938
-48,351 Reduced 28.74%
119,893 $428,000
Q2 2024

Aug 14, 2024

SELL
$5.98 - $9.31 $2.19 Million - $3.42 Million
-366,818 Reduced 68.56%
168,244 $1.04 Million
Q1 2024

May 15, 2024

BUY
$6.7 - $12.0 $1.26 Million - $2.26 Million
188,212 Added 54.26%
535,062 $5.05 Million
Q4 2023

Feb 14, 2024

BUY
$3.18 - $6.86 $980,549 - $2.12 Million
308,349 Added 800.89%
346,850 $2.34 Million
Q3 2023

Nov 14, 2023

SELL
$3.25 - $6.08 $90,324 - $168,975
-27,792 Reduced 41.92%
38,501 $170,000
Q2 2023

Aug 14, 2023

BUY
$2.26 - $3.8 $117,608 - $197,748
52,039 Added 365.08%
66,293 $218,000
Q1 2023

May 15, 2023

BUY
$2.83 - $13.99 $7,264 - $35,912
2,567 Added 21.96%
14,254 $40,000
Q4 2022

Feb 14, 2023

BUY
$5.01 - $8.35 $58,551 - $97,586
11,687 New
11,687 $85,000
Q2 2022

Aug 16, 2022

BUY
$4.2 - $24.0 $96,482 - $551,328
22,972 Added 153.58%
37,930 $186,000
Q1 2022

May 17, 2022

SELL
$9.96 - $23.65 $162,158 - $385,045
-16,281 Reduced 52.12%
14,958 $354,000
Q4 2021

Feb 15, 2022

SELL
$14.0 - $28.44 $261,842 - $531,913
-18,703 Reduced 37.45%
31,239 $552,000
Q3 2021

Nov 16, 2021

BUY
$7.28 - $30.97 $363,577 - $1.55 Million
49,942 New
49,942 $1.41 Million

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $175M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.